on ABIVAX (EPA:ABVX)
Abivax Reveals Strategic Plans for 2026
Abivax has announced its 2026 corporate outlook, focusing on market insights and clinical advancements. With the ulcerative colitis (UC) market predicted to expand significantly, obefazimod is positioned as a potential market leader in this space. This follows positive feedback from the ABTECT Phase 3 safety monitoring report, indicating no new safety concerns.
Abivax anticipates topline results from the ABTECT-UC Phase 3 trial by late Q2 2026, with a regulatory filing in the US planned for late 2026. Concurrently, the ENHANCE-CD Phase 2b trial for Crohn’s disease is underway, with results expected towards the end of 2026. The company’s cash runway extends into Q4 2027.
Additionally, 22 abstracts related to obefazimod will be presented at the European Crohn’s and Colitis Organization conference in February 2026. These developments underline Abivax’s commitment to advancing therapeutic options in chronic inflammatory diseases.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news